Study Confirms REGRANEX® Is Effective Treatment Of Foot Ulcers

Diabetic neuropathic foot ulcers treated with REGRANEX® were 32 percent more likely to heal within 20 weeks than those not treated with REGRANEX® The retrospective patient cohort study utilized a claims database to evaluate more than 24,000 patients with neuropathic diabetic foot ulcers who were treated at specialty wound clinics between 1998 and 2004. Patients who had received REGRANEX® were more likely to have healed at 20 weeks versus those treated with other methods of ulcer care. These results were similar to the results of previous randomized controlled trials of REGRANEX® Gel.

"Clinical studies show how something works in an ideal setting," stated David J. Margolis, M.D., Ph.D., Departments of Dermatology and Biostatistics and Epidemiology, University of Pennsylvania School of Medicine and lead researcher. "Our study looked at how REGRANEX® performs in clinical practice and demonstrated that it achieves similar results in the real world as in the ideal setting."

REGRANEX® Gel is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. When used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control, REGRANEX® Gel increases the incidence of complete healing of diabetic ulcers.

The efficacy of REGRANEX® Gel has not been established for treatment of pressure ulcers and venous stasis ulcers (see Clinical Studies), and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue (Stage I or II, IAET staging classification) or ischemic diabetic ulcers.

For Full Prescribing Information or more information about REGRANEX® Gel, visit https://www.regranex.com.

Wound Repair and Regeneration November-December 2005 edition

===============================

FACT:
Light Exercise Staves Off Heart Failure: Study suggests that low-intensity exercise can delay heart failure in humans and extend the lives of people with congestive heart failure. "We found that low-intensity exercise training markedly delayed the onset of overt CHF without a reduction in antecedent hypertension," concluded researchers at the University of Colorado at Boulder and Ohio State University, in Columbus. "The key findings in this study are that (1) exercise can delay the onset of decompensated heart failure and improve survivability and (2) this effect is strongly dependent on the level of intensity of the exercise. American Physiological Society, news release, Dec. 6, 2005